Cellular approaches to bioreductive drug mechanisms

Cancer and Metastasis Reviews

Volumn 12, Issue 2, 1993, Pages 153-164

  Rauth, A Michael ^a,b   Marshall, Raymond S ^b   Kuehl, Bonnie L ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

bioreductive drug activation; DT diaphorase; mitomycin C; oxygen

Indexed keywords

MISONIDAZOLE; MITOMYCIN; PORFIROMYCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TIRAPAZAMINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CHO CELL; CYTOTOXICITY; DRUG ACTIVATION; DRUG CONFORMATION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPOXIC CELL; NONHUMAN; OXIDATION REDUCTION REACTION; OXYGEN CONCENTRATION; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMAL; ANTINEOPLASTIC AGENTS; CHO CELLS; HAMSTERS; HUMAN; MITOMYCIN; NEOPLASMS; OXIDATION-REDUCTION; OXYGEN; PORFIROMYCIN; SUPPORT, NON-U.S. GOV'T;

EID: 0027323966     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/BF00689807     Document Type: Article

References (71)

1. Potential impact of improvements in radiation therapy on quality of life and survival
2. Tumour hypoxia: its impact on cancer therapy
3. Binding of3H-misonidazole to solid human tumors as a measure of tumor hypoxia
4. Keynote address: Hypoxic cell sensitizers: clinical developments
5. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies
6. Radiosensitizers of hypoxic cells in solid tumors
7. The use of nitroaromatic compounds as hypoxic cell radiosensitizers
8. Chemical sensitizers for hypoxic cells-a decade of experience in clinical radiotherapy
9. Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix
10. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head And Neck Cancer Study (DAHANCA) protocol 5-85
11. Selective chemotherapy of noncycling cells in an in vitro tumor model
12. Hypoxic sensitizer: radiobiological studies at the cellular level
13. Radiosensitizing and toxic effects of the 2-nitroimidazole Ro-07-0582 in hypoxic mammalian cells
14. Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells
15. Pharmacology and toxicology of sensitizers: mechanism studies
16. Combination therapy with radiation and mitomycin C: preliminary results with EMT6 tumor cells in vitro and in vivo
17. Presidential address: Therapeutic attack of hypoxic cells of solid tumors
18. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
19. Redox activation of benzotriazine N-oxides: mechanisms and potential as anticancer drugs
20. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells
21. Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo
22. Free radical formation by antitumor quinones
23. Molecular mechanisms for the hypoxia-dependent activation of 3-ami-no-1,2,4-benzotriazine-1,4-dioxide (SR4233)
24. Oxygen diffusion and oxygen depletion problems in radiobiology
25. Factors affecting the oxygen tension around cells growing in plastic Petri dishes
26. An experimental and analytical study of oxygen depletion in stirred cell suspensions
27. Measurement of low levels of oxygen and their effect on respiration in cell suspensions maintained in an open system
28. Characteristics of hypoxic cells that enhance their susceptibility to chemical injury
29. A thin-film culturing technique allowing rapid gasliquid equilibration (6sec.) with no toxicity to mammalian cells
30. Mechanisms of activation of mitomycin C and AZQ in aerobic and hypoxic mammalian cells
31. Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair deficient mutant
32. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells
33. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro
34. Preclinical studies of porfiromycin as an adjunct to radiotherapy
35. Effects of the mode of administration of mitomycin on tumor and marrow response and on the therapeutic ratio
36. Mitomycin C and radiation
37. Oxygen tension, cellular respiration, and redox state as variables influencing the cytotoxicity of the radiosensitizer misonidazole
38. Human cancer-prone disorders, abnormal carcinogenesis response, and defective DNA metabolism
39. Deficient activation by a human cell strain leads to mitomycin C resistance under aerobic but not hypoxic conditions
40. Mitomycin C resistant L-1210 leukemia cells: association with pleiotropic drug resistance
41. Reduced topoisomerase II and elevated α class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C
42. Role of NADPH: cytochrome C reductase and DT-diaphorase in the biotransformation of mitomycin C
43. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics
44. Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual
45. Human dioxin-inducible cytosolic NAD(P)H: menadione oxidoreductase cDNA sequence and localization of gene to chromosome 16
46. Nucleotide and deduced amino acid sequence of human cDNA (NQO2) corresponding to a second member of the NAD(P) H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6
47. Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin
48. Isolation of Chinese hamster ovary cell mutants deficient in excision repair and mitomycin C bioactivation
49. Chinese hamster ovary cell lines resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase
50. Characterization of L5178Y murine lymphoblasts resistant to quinone antitumor agents
51. Increased sensitivity of quinone resistant cells to mitomycin C
52. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells
53. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin C sensitivity
54. The role of NAD(P)H:quinone oxidoreductase in mitomycin C and porfiromycin resistant human colon cancer HCT 116 cells
55. The sensitivity of human tumor cells to quinone bioreductive drugs: What role for DT-diaphorase?
56. Increased DT-diaphorase activity and cross-resistance to mitomycin C (MMC) in a series of cisplatin-resistant human ovarian carcinoma cell lines
57. Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions
58. Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors
59. Elevation of quinone reductase activity by anticarcinogenic antioxidants
60. Free radicals, antioxidant enzymes and carcinogenesis
61. Transcriptional regulation of the rat NAD(P)H:quinone reductase gene
62. DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family
63. DT-diaphorase activity in various cells in culture emphasis on induction in ascites hepatoma cells
64. High levels of expression of the NAD(P)H:quinone oxidoreductase (NQOI) gene in tumor cells compared to normal cells of the same origin
65. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin C
66. Structureactivity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indolquinones and diaziridinyl benzoquinones